<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">61312</article-id><article-id pub-id-type="doi">10.7554/eLife.61312</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Immunology and Inflammation</subject></subj-group><subj-group subj-group-type="heading"><subject>Microbiology and Infectious Disease</subject></subj-group></article-categories><title-group><article-title>Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-200353"><name><surname>Weisblum</surname><given-names>Yiska</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-9249-1745</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-200356"><name><surname>Schmidt</surname><given-names>Fabian</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-200355"><name><surname>Zhang</surname><given-names>Fengwen</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-200357"><name><surname>DaSilva</surname><given-names>Justin</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-200358"><name><surname>Poston</surname><given-names>Daniel</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-200359"><name><surname>Lorenzi</surname><given-names>Julio CC</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-79944"><name><surname>Muecksch</surname><given-names>Frauke</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-0132-5101</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-200375"><name><surname>Rutkowska</surname><given-names>Magdalena</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-200376"><name><surname>Hoffmann</surname><given-names>Hans-Heinrich</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-97661"><name><surname>Michailidis</surname><given-names>Eleftherios</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-9907-4346</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-200378"><name><surname>Gaebler</surname><given-names>Christian</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="par-7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-200379"><name><surname>Agudelo</surname><given-names>Marianna</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-200380"><name><surname>Cho</surname><given-names>Alice</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-200381"><name><surname>Wang</surname><given-names>Zijun</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-200382"><name><surname>Gazumyan</surname><given-names>Anna</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-200383"><name><surname>Cipolla</surname><given-names>Melissa</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-200384"><name><surname>Luchsinger</surname><given-names>Larry</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-0063-1764</contrib-id><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-200385"><name><surname>Hillyer</surname><given-names>Christopher D</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-200386"><name><surname>Caskey</surname><given-names>Marina</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-193070"><name><surname>Robbiani</surname><given-names>Davide F</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="par-5"/><xref ref-type="other" rid="par-6"/><xref ref-type="fn" rid="conf4"/></contrib><contrib contrib-type="author" id="author-2939"><name><surname>Rice</surname><given-names>Charles M</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-3087-8079</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="par-3"/><xref ref-type="other" rid="par-4"/><xref ref-type="other" rid="par-5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-1153"><name><surname>Nussenzweig</surname><given-names>Michel C</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="other" rid="par-3"/><xref ref-type="fn" rid="conf5"/></contrib><contrib contrib-type="author" corresp="yes" id="author-193060"><name><surname>Hatziioannou</surname><given-names>Theodora</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-2"/><xref ref-type="fn" rid="conf6"/></contrib><contrib contrib-type="author" corresp="yes" id="author-193061"><name><surname>Bieniasz</surname><given-names>Paul D</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-2368-3719</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="cor2">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="conf7"/></contrib><aff id="aff1"><institution content-type="dept">Laboratory of Retrovirology</institution>, <institution>The Rockefeller University</institution>, <addr-line><named-content content-type="city">New York</named-content></addr-line>, <country>United States</country></aff><aff id="aff2"><institution content-type="dept">Laboratory of Molecular Immunology</institution>, <institution>The Rockefeller University</institution>, <addr-line><named-content content-type="city">New York</named-content></addr-line>, <country>United States</country></aff><aff id="aff3"><institution content-type="dept">Laboratory of Vorology and Infectious Disease</institution>, <institution>The Rockefeller University</institution>, <addr-line><named-content content-type="city">New York</named-content></addr-line>, <country>United States</country></aff><aff id="aff4"><institution content-type="dept">Lindsley F. Kimball Research Institute</institution>, <institution>New York Blood Center</institution>, <addr-line><named-content content-type="city">New York City</named-content></addr-line>, <country>United States</country></aff><aff id="aff5"><institution content-type="dept">Lindsley F. Kimball Research Institute</institution>, <institution>New York Blood Center</institution>, <addr-line><named-content content-type="city">New York</named-content></addr-line>, <country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor" id="author-6168"><name><surname>Marsh</surname><given-names>Mark</given-names></name><role>Reviewing editor</role><aff><institution>University Coillege London</institution>, <country>United Kingdom</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><label>*</label>For correspondence: <email>thatziio@rockefeller.edu</email> (TH);</corresp><corresp id="cor2"><label>*</label>For correspondence: <email>pbieniasz@rockefeller.edu</email> (PB);</corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>28</day><month>10</month><year>2020</year></pub-date><volume>9</volume><elocation-id>e61312</elocation-id><history><date date-type="received"><day>22</day><month>07</month><year>2020</year></date><date date-type="accepted"><day>27</day><month>10</month><year>2020</year></date></history><permissions><copyright-statement>Â© 2020, Weisblum et al</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>Weisblum et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link> permitting unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-61312-v1.pdf"/><abstract><p>Neutralizing antibodies elicited by prior infection or vaccination are likely to be key for future protection of individuals and populations against SARS-CoV-2. Moreover, passively administered antibodies are among the most promising therapeutic and prophylactic anti-SARS-CoV-2 agents. However, the degree to which SARS-CoV-2 will adapt to evade neutralizing antibodies is unclear. Using a recombinant chimeric VSV/SARS-CoV-2 reporter virus, we show that functional SARS-CoV-2 S protein variants with mutations in the receptor binding domain (RBD) and N-terminal domain that confer resistance to monoclonal antibodies or convalescent plasma can be readily selected. Notably, SARS-CoV-2 S variants that resist commonly elicited neutralizing antibodies are now present at low frequencies in circulating SARS-CoV-2 populations. Finally, the emergence of antibody-resistant SARS-CoV-2 variants that might limit the therapeutic usefulness of monoclonal antibodies can be mitigated by the use of antibody combinations that target distinct neutralizing epitopes.</p></abstract><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Viruses</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000060</institution-id><institution>National Institute of Allergy and Infectious Diseases</institution></institution-wrap></funding-source><award-id>R37AI64003</award-id><principal-award-recipient><name><surname>Bieniasz</surname><given-names>Paul D</given-names></name></principal-award-recipient></award-group><award-group id="par-2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000060</institution-id><institution>National Institute of Allergy and Infectious Diseases</institution></institution-wrap></funding-source><award-id>R01AI078788</award-id><principal-award-recipient><name><surname>Hatziioannou</surname><given-names>Theodora</given-names></name></principal-award-recipient></award-group><award-group id="par-3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000060</institution-id><institution>National Institute of Allergy and Infectious Diseases</institution></institution-wrap></funding-source><award-id>P01AI138398-S1,2U19AI111825</award-id><principal-award-recipient><name><surname>Rice</surname><given-names>Charles M</given-names></name><name><surname>Nussenzweig</surname><given-names>Michel C</given-names></name></principal-award-recipient></award-group><award-group id="par-4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000060</institution-id><institution>National Institute of Allergy and Infectious Diseases</institution></institution-wrap></funding-source><award-id>R01AI091707-10S1</award-id><principal-award-recipient><name><surname>Rice</surname><given-names>Charles M</given-names></name></principal-award-recipient></award-group><award-group id="par-5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100006369</institution-id><institution>George Mason University</institution></institution-wrap></funding-source><award-id>Fast Grant</award-id><principal-award-recipient><name><surname>Robbiani</surname><given-names>Davide F</given-names></name><name><surname>Rice</surname><given-names>Charles M</given-names></name></principal-award-recipient></award-group><award-group id="par-6"><funding-source><institution-wrap><institution>European ATAC Consortium</institution></institution-wrap></funding-source><award-id>EC101003650</award-id><principal-award-recipient><name><surname>Robbiani</surname><given-names>Davide F</given-names></name></principal-award-recipient></award-group><award-group id="par-7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>UL1 TR001866</award-id><principal-award-recipient><name><surname>Gaebler</surname><given-names>Christian</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group></article-meta></front><back><sec id="s1" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interest</title><fn fn-type="conflict" id="conf2"><p>Yiska Weisblum, Rockefeller University has applied for a patent relating to the replication compentent VSV/SARS-CoV-2 chimeric virus on which YW is listed as an inventor (US patent 63/036,124).</p></fn><fn fn-type="conflict" id="conf3"><p>Fabian Schmidt, Rockefeller University has applied for a patent relating to the replication compentent VSV/SARS-CoV-2 chimeric virus on which FS is listed as an inventor (US patent 63/036,124).</p></fn><fn fn-type="conflict" id="conf4"><p>Davide F Robbiani, Rockefeller University has applied for a patent relating to SARS-CoV-2 monoclonal antibodies on which DFR is listed as an inventor.</p></fn><fn fn-type="conflict" id="conf5"><p>Michel C Nussenzweig, Rockefeller University has applied for a patent relating to SARS-CoV-2 monoclonal antibodies on which MCN is listed as an inventor.</p></fn><fn fn-type="conflict" id="conf6"><p>Theodora Hatziioannou, Rockefeller University has applied for a patent relating to the replication compentent VSV/SARS-CoV-2 chimeric virus on which TH is listed as an inventor (US patent 63/036,124).</p></fn><fn fn-type="conflict" id="conf7"><p>Paul D Bieniasz, Rockefeller University has applied for a patent relating to the replication compentent VSV/SARS-CoV-2 chimeric virus on which PDB is listed as an inventor (US patent 63/036,124).</p></fn><fn fn-type="conflict" id="conf1"><p>The other authors declare that no competing interests exist.</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Human subjects: Human plasma samples were obtained from volunteers at the New York Blood Center and Rockefeller University Hospital. Informed consent, and consent to publishers obtained. De-identified Plasma samples from the New York Blood Center were obtained under protocols approved by Institutional Review Boards at the New York Blood Center and authorized by donors under informed consent in accordance with federal, state and local laws and regulations which address protection of human subjects in research, including 45 CFR part 46. Plasma samples at the Rockefeller University were collected with  Informed consent, and consent to publishers after review by the Rockefeller University IRB protocol number DRO-1006.</p></fn></fn-group></sec><sec id="s2" sec-type="supplementary-material"><title>Additional Files</title><sec id="s3" sec-type="data-availability"><title>Data availability</title><p>All data generated or analysed during this study are included in the manuscript and supporting files</p></sec><supplementary-material><ext-link xlink:href="elife-61312-supp-v1.zip">Download zip</ext-link><p>Any figures and tables for this article are included in the PDF. The zip folder contains additional supplemental files.</p></supplementary-material></sec></back></article>